1. An apparatus comprising:
a first communication path and a second communication path exposed to a common mode transient, exposure to the common mode transient inducing a first common mode transient signal onto the first communication path and a second common mode transient signal onto the second communication path;
a monitor circuit to derive an adjustment signal based on detected presence of the second common mode transient signal present on the second communication path; and
a gain modifier circuit to modify a gain setting applied to subsequent derived adjustment signals produced by the monitor circuit, the gain setting applied to more closely match the gain-modified adjustment signals to common mode transient signals on the first communication path.
2. The apparatus as in claim 1, wherein the gain-modified adjustment signals cancel corresponding common mode transient signals on the first communication path.
3. The apparatus as in claim 1, wherein the gain-modified adjustment signals are simulated current drive signals outputted from the monitor circuit to the first communication path.
4. The apparatus as in claim 1, wherein the gain setting accounts for a mismatch in series capacitance between the first communication path and the second communication path.
5. The apparatus as in claim 1, wherein the first communication path supports conveyance of a first signal of a differential signal pair; and
wherein the second communication path is allocated to detect presence of common mode transients.
6. The apparatus as in claim 1, wherein the gain modifier circuit receives feedback from a comparator circuit that monitors the first communication path, the gain modifier circuit utilizing the feedback to adjust the gain setting.
7. The apparatus as in claim 6, wherein the feedback indicates whether a magnitude of given adjustment signal matches a magnitude of a corresponding common mode transient signal present on the first communication path.
8. The apparatus as in claim 7, wherein a trim circuit modifies a threshold setting of the comparator circuit to produce the feedback, the comparator circuit monitoring a mismatch between the given adjustment signal and the corresponding common mode transient signal present on the first communication path.
9. The apparatus as in claim 1, wherein the control circuit initiates simultaneously driving both the first communication path and the second communication path with DC signals during a test mode.
10. The apparatus as in claim 1 further comprising;
a gain circuit, the gain circuit applying the gain setting to gain-adjust a subsequent transient signal detected on the second communication path, the gain circuit outputting the gain-adjusted subsequent transient signal to the first communication path.
11. A method comprising:
exposing a first communication path and a second communication path to a common mode transient, exposure to the common mode transient inducing a first common mode transient signal onto the first communication path and a second common mode transient signal onto the second communication path;
operating a monitor circuit to derive an adjustment signal based on detected presence of the second common mode transient signal in the second communication path; and
modifying a gain setting applied to subsequent derived adjustment signals to more closely match the gain-modified adjustment signals to common mode transient signals on the first communication path.
12. The method as in claim 11 further comprising:
utilizing the gain modified adjustment signals to cancel the common mode transient signals on the first communication path.
13. The method as in claim 11, wherein the gain modified adjustment signals are simulated current drive signals outputted from a monitor circuit to the first communication path.
14. The method as in claim 11, wherein a setting of the gain accounts for a mismatch in series capacitance between the first communication path and the second communication path.
15. The method as in claim 11, wherein the first communication path supports conveyance of a first signal of a differential signal pair; and
wherein the second communication path is allocated to test for presence of common mode transients.
16. The method as in claim 11, wherein modifying the gain setting further comprises:
receiving feedback from a comparator circuit that monitors the first communication path; and
utilizing the feedback to adjust the gain setting.
17. The method as in claim 16, wherein the feedback indicates whether a magnitude of given adjustment signal matches a magnitude of a corresponding common mode transient signal present on the first communication path.
18. The method as in claim 17 further comprising:
modifying a threshold setting of the comparator circuit to produce the feedback, the comparator circuit monitoring for a mismatch between the given adjustment signal and the corresponding common mode transient signal present on the first communication path.
19. The method as in claim 11, wherein exposing the first communication path and the second communication path further comprises:
during exposure, simultaneously driving both the first communication path and the second communication path with DC signals.
20. The method as in claim 11 further comprising:
subsequent to modifying the gain setting, utilizing the first communication path to communicate a communication signal to a target recipient;
applying the gain setting to gain-adjust a subsequent transient signal detected on the second communication path; and
applying the gain-adjusted subsequent transient signal to the first communication path.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. (canceled)
2. (canceled)
3. A method of producing a cellular drug release, comprising:
(a) providing a composition comprising a therapeutically effective amount of a pharmacological agent loaded onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces;
(b) exposing a cell to the composition;
(c) causing entry of the mesoporous HAP into the cell and dissolving of the mesoporous HAP in the lysosomes of the cell and release of the pharmacological agent from the mesoporous HAP;
(d) causing the pharmacological agent to release from the lysosomes and enter the cytoplasm; and
(e) causing the pharmacological agent to be pumped out of the cell.
4. The method of claim 3, wherein the pharmacological agent comprises an antidepressant.
5. The method of claim 4, wherein in step (e) the pharmacological agent is released into the blood stream of the animal.
6. The method of claim 5, wherein the pharmacological agent is released continuously into the blood stream of the animal continuously for a period of 4 weeks or longer than 4 weeks without an intermittent cessation.
7. The method of claim 6, wherein the pharmacological agent is released into the blood stream of the animal continuously for a period of 5 weeks or longer than 5 weeks.
8. The method of claim 3, wherein the cell is present in an animal and exposed to the composition via intramuscular injection of the pharmacological agent to the animal.
9. The method of claim 4, wherein the cell comprises neutrophils, monocytes, macrophages, dendritic cells, and mast cells.
10. The method of claim 3, further comprising causing an increase in Ca2+ and PO43\u2212 ions within the lysosomes of the cell.
11. The method of claim 3, wherein the mesoporous HAP comprises HAP particles with each particle having a size of ranging from 500 to 3700 nm.
12. The method of claim 3, wherein the mesoporous HAP with hydrophobic surfaces comprises:
a) mesoporous hydroxyapatite (HAP);
b) acrylic acid, grafted onto the surface of the mesoporous HAP and forming an acrylic acid-grafted mesoporous HAP; and
c) a pharmaceutically acceptable amphiphilic compound, modifying the surface of the acrylic acid-grafted mesoporous HAP and forming hydrophobic hydrocarbon tails on the surfaces thereof.
13. The method of claim 12, wherein the amphiphilic compound comprises a fatty acid from between 10 to 40 carbon atoms.
14. The method of claim 13, wherein the fatty acid is selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, elaidic acid, oleic acid, linoleic acid, polyunsaturated elaidolinoleic acid, polyunsaturated linolenic acid, elaidolinolenic acid, polyunsaturated ricinoleic acid, arachidic acid, behenic acid, erucic acid, lignoceric acid, ceric acid, montanic acid, melissic acid, and geddic acid.
15. The method of claim 12, wherein the amphiphilic compound comprises linoleic acid.
16. The method of claim 3, wherein the mesoporous hydroxyapatite (HAP) contains no water-soluble polyvalent metal compound, andor calcium as a constituent of hydroxyapatite is not substituted by other metal.
17. The method of claim 12, wherein the amphiphilic compound comprises a pharmaceutically acceptable surfactant.
18. The method of claim 17, wherein the pharmaceutically acceptable surfactant comprises a polyoxyethylene glycolated natural or hydrogenated vegetable oil, or hydrogenated castor oil.
19. The method of chum 17, wherein the pharmaceutically acceptable surfactant is at least one selected from the group consisting of sodium lauryl sulfate, polyoxyethylenesorbitan monolaurate, cetyltrimethylammoniumbromide, polyoxyl castor oil, hexadecyltrimethylammonium bromide, polyethylene glycol tert-octylphenyl ether, nonylphenol ethoxylate, cyclodextrins, and lecithin.
20. (canceled)
21. The method of claim 3, wherein the composition comprises:
(a) mesoporous hydroxyapatite (HAP);
(b) acrylic acid, grafted onto the surfaces of the mesoporous HAP and forming an acrylic acid-grafted mesoporous HAP;
(c) linoleic acid, modifying the surfaces of the acrylic acid-grafted mesoporous HAP and forming hydrophobic hydrocarbon tails on the surfaces thereof; and
(d) a therapeutically effective amount of an antidepressant loaded onto the hydrophobic hydrocarbon tails.
22. The method of claim 21, wherein the composition exhibits the following characteristics:
(i) release of less than 10% of the antidepresant from the mesoporous HAP in a fluid having a pH value of about 7.4; and
(ii) release of the antidepresant in a fluid having a pH value of about \u22665.
23. The method of claim 21, wherein the composition comprises a therapeutically effective amount of a pharmacological agent loaded onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces.